eamdacademy.org-7YNE-1792519510-a764521438 1792519510 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2025 4 1 Bruno Martins Lucas Pereira Renata Azevedo Pedro Costa 2025 10.68159/a764521438 https://eamdacademy.org/pub/journal/3/article/a764521438 Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500-25. Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10(3):721-5. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-94. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles—from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982-7015. Thi TT, Suys EJ, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines (Basel). 2021;9(4):359. Taha MS, Padmakumar S, Singh A, Amiji MM. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation. Drug Deliv Transl Res. 2020;10(3):766-90. Bonaccorso A, Russo G, Pappalardo F, Carbone C, Puglisi G, Pignatello R, et al. Quality by design tools reducing the gap from bench to bedside for nanomedicine. Eur J Pharm Biopharm. 2021;169:144-55. Rawal M, Singh A, Amiji MM. Quality-by-design concepts to improve nanotechnology-based drug development. Pharm Res. 2019;36(11):153. Csóka I, Ismail R, Jójárt-Laczkovich O, Pallagi E. Regulatory considerations, challenges and risk-based approach in nanomedicine development. Curr Med Chem. 2021;28(36):7461-76. Mühlebach S. Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? Adv Drug Deliv Rev. 2018;131:122-31. Ali F, Neha K, Parveen S. Current regulatory landscape of nanomaterials and nanomedicines: a global perspective. J Drug Deliv Sci Technol. 2023;80:104118. Zagalo DM, Silva BM, Silva C, Simoes S, Sousa JJ. A quality by design approach in pharmaceutical development of lipid-based nanosystems: a systematic review. J Drug Deliv Sci Technol. 2022;70:103207. Evers MJ, Kulkarni JA, van der Meel R, Cullis PR, Vader P, Schiffelers RM. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods. 2018;2(9):1700375. Roces CB, Lou G, Jain N, Abraham S, Thomas A, Halbert GW, et al. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics. 2020;12(11):1095. Maeki M, Fujishima Y, Sato Y, Yasui T, Kaji N, Ishida A, et al. Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers. PLoS One. 2017;12(11):e0187962. Colombo S, Beck-Broichsitter M, Bøtker JP, Malmsten M, Rantanen J, Bohr A. Transforming nanomedicine manufacturing toward quality by design and microfluidics. Adv Drug Deliv Rev. 2018;128:115-31. Osouli-Bostanabad K, Puliga S, Serrano DR, Bucchi A, Halbert G, Lalatsa A. Microfluidic manufacture of lipid-based nanomedicines. Pharmaceutics. 2022;14(9):1940. Prakash G, Shokr A, Willemen N, Bashir SM, Shin SR, Hassan S. Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev. 2022;184:114197. Khadke S, Roces CB, Donaghey R, Giacobbo V, Su Y, Perrie Y. Scalable solvent-free production of liposomes. J Pharm Pharmacol. 2020;72(10):1328-40. Worsham RD, Thomas V, Farid SS. Potential of continuous manufacturing for liposomal drug products. Biotechnol J. 2019;14(2):1700740. Forbes N, Hussain MT, Briuglia ML, Edwards DP, Ter Horst JH, Szita N, et al. Rapid and scale-independent microfluidic manufacture of liposomes entrapping protein incorporating in-line purification and at-line size monitoring. Int J Pharm. 2019;556:68-81. Shen Y, Gwak H, Han B. Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics. Analyst. 2024;149(3):614-37. Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, et al. Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics. 2022;14(9):1886. Operti MC, Bernhardt A, Grimm S, Engel A, Figdor CG, Tagit O. PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up. Int J Pharm. 2021;605:120807. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Scale-up polymeric-based nanoparticles drug delivery systems: development and challenges. OpenNano. 2022;7:100048. Matsuura-Sawada Y, Maeki M, Nishioka T, Niwa A, Yamauchi J, Mizoguchi M, et al. Microfluidic device-enabled mass production of lipid-based nanoparticles for applications in nanomedicine and cosmetics. ACS Appl Nano Mater. 2022;5(6):7867-76. Riewe J, Erfle P, Melzig S, Kwade A, Dietzel A, Bunjes H. Antisolvent precipitation of lipid nanoparticles in microfluidic systems: a comparative study. Int J Pharm. 2020;579:119167. Glader C, Jeitler R, Wang Y, Tetyczka C, Schlömer M, et al. Establishment of a semi-continuous nano-production line using the Microfluidizer® technology for the fabrication of lipid-based nanoparticles. Part 1: Screening of critical parameters and design of experiment optimization studies. Eur J Pharm Sci. 2024;203:106928. Glader C, Jeitler R, Wang Y, Urich JA, Tetyczka C, Caisse P, et al. Formulation optimization and real-time size monitoring in the semi-continuous production of edaravone-loaded lipid-based nanocarriers using the Microfluidizer® technology. Part 2. Eur J Pharm Sci. 2025;214:107306. Javid-Naderi MJ, Shaegh SA. Advanced microfluidic techniques for the preparation of solid lipid nanoparticles: innovations and biomedical applications. Int J Pharm X. 2025;12:100399. Operti MC, Bernhardt A, Sincari V, Jager E, Grimm S, Engel A, et al. Industrial scale manufacturing and downstream processing of PLGA-based nanomedicines suitable for fully continuous operation. Pharmaceutics. 2022;14(2):276. Younis MA, Tawfeek HM, Abdellatif AA, Abdel-Aleem JA, Harashima H. Clinical translation of nanomedicines: challenges, opportunities, and keys. Adv Drug Deliv Rev. 2022;181:114083.